camostat has been researched along with Renal Insufficiency, Chronic in 3 studies
camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Previously, we reported that a synthetic serine protease inhibitor, camostat mesilate (CM), mitigated hypertension and proteinuria in rodent disease models." | 8.02 | A serine protease inhibitor camostat mesilate prevents podocyte apoptosis and attenuates podocyte injury in metabolic syndrome model rats. ( Adachi, M; Deng, Q; Hayata, M; Iwata, Y; Izumi, Y; Kakizoe, Y; Kitamura, K; Kuwabara, T; Miyasato, Y; Miyoshi, T; Mizumoto, T; Morinaga, J; Mukoyama, M; Nakagawa, T; Sakai, Y; Tomita, K; Uchimura, K, 2021) |
| " Previously, we reported that a synthetic serine protease inhibitor, camostat mesilate (CM), mitigated hypertension and proteinuria in rodent disease models." | 4.02 | A serine protease inhibitor camostat mesilate prevents podocyte apoptosis and attenuates podocyte injury in metabolic syndrome model rats. ( Adachi, M; Deng, Q; Hayata, M; Iwata, Y; Izumi, Y; Kakizoe, Y; Kitamura, K; Kuwabara, T; Miyasato, Y; Miyoshi, T; Mizumoto, T; Morinaga, J; Mukoyama, M; Nakagawa, T; Sakai, Y; Tomita, K; Uchimura, K, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Mizumoto, T | 3 |
| Kakizoe, Y | 3 |
| Nakagawa, T | 2 |
| Iwata, Y | 1 |
| Miyasato, Y | 3 |
| Uchimura, K | 3 |
| Adachi, M | 3 |
| Deng, Q | 1 |
| Hayata, M | 3 |
| Morinaga, J | 3 |
| Miyoshi, T | 3 |
| Izumi, Y | 1 |
| Kuwabara, T | 1 |
| Sakai, Y | 3 |
| Tomita, K | 1 |
| Kitamura, K | 3 |
| Mukoyama, M | 3 |
| Ueda, M | 2 |
| Narita, Y | 2 |
| Shiraishi, N | 1 |
| Kadowaki, D | 2 |
| Hirata, S | 1 |
3 other studies available for camostat and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
A serine protease inhibitor camostat mesilate prevents podocyte apoptosis and attenuates podocyte injury in metabolic syndrome model rats.
Topics: Animals; Apoptosis; Cells, Cultured; Disease Models, Animal; Esters; Guanidines; Hypertension; Male; | 2021 |
The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects.
Topics: Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Creatinine; Disease Progression; Est | 2015 |
Combination therapy with renin-angiotensin-aldosterone system inhibitor telmisartan and serine protease inhibitor camostat mesilate provides further renoprotection in a rat chronic kidney disease model.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazol | 2016 |